PALVELLA THERAPEUTICS, INC.
PVLA$197M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWAYNE14 employees
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
PVLA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Vehicle
Pachyonychia Congenita
QTORIN 3.9% Rapamycin Anhydrous Gel
Microcystic Lymphatic Malformation
PTX-022
Pachyonychia Congenita
Vehicle comparator
BCCs in Gorlin Syndrome Patients
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vehicle | Phase 3 | Pachyonychia Congenita | - | - |
QTORIN 3.9% Rapamycin Anhydrous Gel | Phase 3 | Microcystic Lymphatic Malformation | - | - |
PTX-022 | Phase 3 | Pachyonychia Congenita | - | - |
Vehicle comparator | Phase 2 | BCCs in Gorlin Syndrome Patients | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply